Second Cancer Risk in Female Survivors of Hodgkin Lymphoma: A National Cohort Analysis Across Treatment Eras

PURPOSE: Subsequent primary malignancies (SPMs) are the leading cause of long-term treatment-related mortality in Hodgkin lymphoma (HL). Although treatments have evolved substantially over recent decades, few studies have demonstrated reductions in SPM risks following modern treatments, nor how such changes should inform survivorship care and screening. We analyzed SPM risks in a large female cohort of childhood and adult patients with HL treated over a 60-year period. MATERIALS AND METHODS: This population-based cohort study included 7,428 women diagnosed with HL before age 36 years in England and Wales from 1954 to 2010, with follow-up through 2018. SPMs were ascertained via national cancer registry linkages. Standardized incidence ratios (SIRs), absolute excess risks, and multivariable models were used to assess temporal trends and associations with treatment. RESULTS: During a median follow-up of 20.2 years, 1,200 women developed 1,467 invasive cancers (SIR, 3.3 [95% CI, 3.1 to 3.5]), most commonly breast, lung, and thyroid cancers. Solid tumor risks were the highest following radiotherapy, with a strong dose-dependent response. Alkylator use with radiotherapy was associated with reduced risks of breast cancer but increased risks of GI cancers. Solid cancer risks decreased by 25% between treatment periods 1954-1989 and 2000-2010. The decrease was attenuated and nonsignificant after adjustment for radiotherapy but not affected by adjustment for chemotherapy. No decline was observed for hematologic malignancies. Cumulative incidence of SPMs reached 36% at 50 years. CONCLUSION: Female patients treated in more recent eras have a substantially lower long-term risk of solid SPMs largely attributable to the reduced use, dose, and improvement in radiotherapy. Nevertheless, persistently elevated risks remained beyond 50 years of follow-up, particularly for lung and breast cancer, underscoring the need for lifelong surveillance and targeted screening of survivors.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Oncology
Published
2026-11-12
DOI
https://doi.org/10.1200/jco-26-00418
Primary Topic
Multiple and Secondary Primary Cancers
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Second Cancer Risk in Female Survivors of Hodgkin Lymphoma: A National Cohort Analysis Across Treatment Eras

Lisa Lowry, John A. Radford, George Follows, Murray Brunt et al.
Journal of Clinical Oncology
Multiple and Secondary Primary Cancers
article

Second Cancer Risk in Female Survivors of Hodgkin Lymphoma: A National Cohort Analysis Across Treatment Eras

Lisa Lowry, John A. Radford, George Follows, Murray Brunt, Kim Benstead, Anjali M Zarkar, Peter Hoskin, Michael Emlyn Jones, Ian Chau, Christian David Mallen, Anthony J. Swerdlow, Aislinn Macklin-Doherty, Clive Irwin, Amy Berrington de González, David Cunningham, Mark Bower, John G. Gribben, Andrew S. Bates, Isabel Syndikus, Paul A. Fields, John A. Frew, Emma Thomas
article en

Abstract

PURPOSE: Subsequent primary malignancies (SPMs) are the leading cause of long-term treatment-related mortality in Hodgkin lymphoma (HL). Although treatments have evolved substantially over recent decades, few studies have demonstrated reductions in SPM risks following modern treatments, nor how such changes should inform survivorship care and screening. We analyzed SPM risks in a large female cohort of childhood and adult patients with HL treated over a 60-year period. MATERIALS AND METHODS: This population-based cohort study included 7,428 women diagnosed with HL before age 36 years in England and Wales from 1954 to 2010, with follow-up through 2018. SPMs were ascertained via national cancer registry linkages. Standardized incidence ratios (SIRs), absolute excess risks, and multivariable models were used to assess temporal trends and associations with treatment. RESULTS: During a median follow-up of 20.2 years, 1,200 women developed 1,467 invasive cancers (SIR, 3.3 [95% CI, 3.1 to 3.5]), most commonly breast, lung, and thyroid cancers. Solid tumor risks were the highest following radiotherapy, with a strong dose-dependent response. Alkylator use with radiotherapy was associated with reduced risks of breast cancer but increased risks of GI cancers. Solid cancer risks decreased by 25% between treatment periods 1954-1989 and 2000-2010. The decrease was attenuated and nonsignificant after adjustment for radiotherapy but not affected by adjustment for chemotherapy. No decline was observed for hematologic malignancies. Cumulative incidence of SPMs reached 36% at 50 years. CONCLUSION: Female patients treated in more recent eras have a substantially lower long-term risk of solid SPMs largely attributable to the reduced use, dose, and improvement in radiotherapy. Nevertheless, persistently elevated risks remained beyond 50 years of follow-up, particularly for lung and breast cancer, underscoring the need for lifelong surveillance and targeted screening of survivors.

Journal of Clinical Oncology
Royal Marsden NHS Foundation Trust (GB), Nottingham University Hospitals NHS Trust (GB), University of Nottingham (GB), Institute of Cancer Research (GB), Queen Mary University of London (GB), Guy's and St Thomas' NHS Foundation Trust (GB), University of Cambridge (GB), Queen Elizabeth Hospital Birmingham (GB), St James's University Hospital (GB), University Hospital Coventry (GB), Freeman Hospital (GB), Gloucestershire Hospitals NHS Foundation Trust (GB), University Hospital Southampton NHS Foundation Trust (GB), Clatterbridge Cancer Centre NHS Foundation Trust (GB), University of Manchester (GB), Queen Elizabeth Hospital (GB), Mount Vernon Cancer Centre (GB), Royal Marsden Hospital (GB), The Christie NHS Foundation Trust (GB), Addenbrooke's Hospital (GB), NIHR Biomedical Research Centre at The Royal Marsden and the ICR (GB), Barts Cancer Institute (GB), Imperial College London (GB), Keele University (GB)
Good health and well-being
Multiple and Secondary Primary Cancers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon